Bayer's Raised 2026 Targets Meet a Split Broker Reaction and a Fresh FDA Win
Published on 11/10/2026 at 07:21 | Editorial boerse-global.de
Bayer shares advanced 3.3% in the session after the German life-sciences group lifted its medium-term profitability outlook, with two major investment banks responding to the update in sharply different fashion.
The Leverkusen-based company now expects EBITDA before special items of EUR 9.8 billion to EUR 10.3 billion for fiscal 2026, an upgrade announced on 3 November. Free cash flow guidance for the same year was also nudged higher, though it stays in negative territory at minus EUR 1.5 billion to minus EUR 0.5 billion.
Those targets landed alongside third-quarter 2026 results. Group revenue reached EUR 10.1 billion, a gain of 4.1% on a reported basis and 1.9% once currency and portfolio effects are stripped out, according to company figures. EBITDA before special items climbed to EUR 1.62 billion, an increase of 6.9%.
Should investors sell immediately? Or is it worth buying Bayer?
Brokers Diverge on the Same Set of Numbers
Jefferies raised its price target to EUR 48.50 from EUR 46 on Thursday, the day after the quarterly release, while keeping its "Hold" rating intact. Goldman Sachs moved the other direction on the rating scale but further on price: on 4 November it lifted its target to EUR 66.00 from EUR 63.50 and, according to media reports, maintained a "Buy" recommendation. The two actions frame a wide gap in how the sell side views the stock's upside.
Beyond the quarterly figures, Bayer disclosed a regulatory milestone. The US Food and Drug Administration has cleared its active ingredient Asundexian under the brand name Sunharbo, Reuters reported. The approval covers reducing the risk of stroke in certain adults who have suffered an ischemic stroke or a high-risk transient ischemic attack. Bayer said the drug is to be used in combination with an antiplatelet therapy, and the green light applies specifically to that patient group and that combination regimen.
Roundup Settlement Awaits Court Review
On the litigation front, Chief Executive Bill Anderson said on 3 November that the proposed USD 7.25 billion settlement should be finalized before Christmas, according to Reuters. At the time of his remarks the agreement was before a court in Missouri for review, with Bayer anticipating a further procedural step before the holiday period.
Separately, the company outlined expansion plans for its biologicals business in Latin America. Bayer said on 4 November that it intends to bring a total of 17 new biological products to the region by 2030. The lineup, per the Reuters report, includes biopesticides as well as products designed to improve plant performance — a multi-year rollout confined to that market.
Ad
Bayer Stock: New Analysis - 10 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
